Overview

 
AiCuris currently focuses on drug development up to clinical validation. Commercialization of AiCuris’ products is realized through strategic collaboration with appropriate parties.
 

 


 

 

Successful commercialization of Prevymis® (Letermovir) by Merck & Co., USA (MSD). In 2012 AiCuris entered into an exclusive worldwide license agreement for its portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including Letermovir, that resulted in successful registration of the drug on major markets with growing revenues (over $280 million in 2020) and block-buster potential in the upcoming years.


 

 
To optimize the royalty flow and to boost the company´s development pipeline, AiCuris signed a deal with Royalty Pharma for a monetization of partial royalty flow for Prevymis®. This deal supports the company´s more expensive development of late-stage assets, while keeping the major part of the royalty and milestones stream with AiCuris.

 
As a company not limited to one proprietary platform or technology, AiCuris always aims to identify novel approaches in research & development to help us make a real difference in the anti-infective field.
 

 
To explore a radically new approach to fight severe bacterial infections, AiCuris signed a deal with Lysando in 2019. This deal grants AiCuris access to a new technology –  Artilysins®, a new class of fusion proteins with a novel mode of action to potentially replace conventional antibiotics. These drugs could provide a breakthrough in fighting antimicrobial resistance (AMR), while also solving indications of urgent unmet need in antibacterial therapy.

 


If you or your company are interested in partnering with AiCuris, please contact us.